Results from Cognition’s Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) was presented at the Alzheimer’s Association International Conference (AAIC 2025) by Dr. James Galvin, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the SHIMMER study director. An archive of this oral presentation is below.
Additionally, results from the Phase 2 COG0201 ‘SHINE’ study (NCT03507790) of zervimesine in Alzheimer’s disease were presented in a poster. Two research posters were also presented pertaining to the mechanism that underlies the impact of zervimesine in Alzheimer’s disease. These posters summarize analyses of the cerebrospinal fluid (CSF) and plasma biomarkers from SHINE participants with lower levels of p-tau217.
Poster Presentations:
- Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum (view poster here)
- Exploratory CSF proteomic analysis of a pre-specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine (view poster here)
- Plasma proteomic analysis of a biomarker-defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer’s disease participants (view poster here)
Oral session:
- Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)